KAHR
Jerusalem, Israel · Founded 2005
- Headquarters
- Jerusalem
- Employees
- 11–50
- Founded
- 2005
- Business Model
- B2B
- Website
- kahrmedical.com
- Last Round
- Series AFeb 2020
- Rounds
- 2
About
KAHR Medical is a clinical-stage Israeli biotechnology company that develops proprietary bispecific fusion protein therapeutics designed to modulate immune checkpoints for the treatment of cancer and autoimmune diseases. Founded in 2005 and headquartered in Jerusalem, the company's pipeline includes first-in-class T-cell engagers aimed at transforming immunotherapy for indications such as microsatellite-stable colorectal cancer. KAHR Medical has raised funding across multiple rounds, including Series B financing, to advance its immunotherapeutics platform toward clinical development.
Summary
KAHR is a Biotech company based in Jerusalem, Israel, founded in 2005. Its most recent funding was a Series A round in Feb 2020. Investors include Oriella Limited, Pavilion Capital and Mirae Asset Venture Investment.
Funding History
Feb 2020
Sign up to see all 2 rounds
Seed through Series A — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/kahr"><img src="https://indexed.vc/api/badge/company/kahr" alt="KAHR on Indexed.vc" width="260" height="76" /></a>